N-[3-(aminomethyl)benzyl]acetamidine (1400 W) as a potential immunomodulatory agent

Anna Mertas1, Hanna Duliban2, Ewelina Szliszka1

  • 1Department of Microbiology and Immunology, Medical University of Silesia in Katowice, Jordana 19, 41 808 Zabrze, Poland.

Insights

The selective inducible nitric oxide synthase (iNOS) inhibitor 1400W effectively reduced nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α) while increasing interleukin-12 (IL-12) production in macrophages.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Macrophages play a critical role in immune responses.
  • Nitric oxide (NO), IL-12, and TNF-α are key inflammatory mediators.
  • Inducible nitric oxide synthase (iNOS) is a crucial enzyme in NO production.

Purpose of the Study:

  • To investigate the effects of selective iNOS inhibitors on NO, IL-12, and TNF-α production.
  • To compare the efficacy of 1400W, L-NIL, and L-NMMA on cytokine release.
  • To explore the role of exogenous NO in modulating IL-12 and TNF-α production.

Main Methods:

  • J774A.1 macrophages were activated with LPS and IFN-γ.
  • Cells were treated with iNOS inhibitors: 1400W, L-NMMA, and L-NIL.
  • NO production was measured, along with IL-12 p40 and TNF-α secretion.
  • The effect of NO donor S-NO-Cap on cytokine production was assessed.

Main Results:

  • 1400W potently inhibited NO generation and decreased TNF-α release while increasing IL-12 p40 secretion.
  • L-NIL suppressed NO and TNF-α but did not affect IL-12 p40.
  • L-NMMA showed weaker inhibition of NO and a non-significant decrease in TNF-α.
  • Exogenous NO (S-NO-Cap) inhibited IL-12 p40 production in a dose-dependent manner.

Conclusions:

  • 1400W demonstrates significant potential as a therapeutic agent for modulating iNOS activity and cytokine profiles.
  • Selective iNOS inhibition offers a promising strategy for managing inflammatory conditions.
  • The distinct effects of different NOS inhibitors highlight the complexity of NO-mediated immune regulation.